As a result, ARID1A mutants displayed significantly elevated VEGFA expression, ERBB2 signaling, FGFR2 signaling, and CLDN18 expression, yet equal EGFR signaling and c-Met signaling to WT GC tumors. This evidence concerns the gene FGFR2 and gastric cancer.